'Good' Bacteria Could Fight Hospital Infections
C. difficile is the most common cause of healthcare-associated infection in U.S. hospitals. Recurrence occurs in 25 to 30 percent of patients, experts say. Toxic strains of C. difficile bacteria cause diarrhoea, abdominal cramps and, in some cases, severe inflammation of the colon.
The infection commonly affects people during or after a hospital stay, particularly those who have had a long course of antibiotics or have a weakened immune system. Prolonged antibiotic use can knock out "good" gut bacteria that would normally keep toxin-producing strains of C. difficile in check.
"The antibiotics don't completely get rid of the C. diff bacteria, and if the patient hasn't developed an immune response against the toxin the bacteria produces, they'll get sick again," said lead author Dale Gerding, MD, a professor of medicine at Loyola University Chicago Stritch School of Medicine.
Dr. Gerding and his colleagues tried a new approach: After patients were successfully treated with an antibiotic, the researchers gave them a non-toxic strain of C. difficile. They theorised that the good bug would crowd out what remained of its toxic cousin.
The study sample, 173 patients (18 years or older), was randomly assigned to four groups: three that received different doses of non-toxic C. difficile, and one that was given a placebo. The good C. difficile, Dr. Gerding noted, is completely natural -- with no genetic tweaking. Treatment involved drinking a colourless, odourless liquid once a day, for one week.
Of 125 patients who received the treatment, only 11 percent had a recurrent infection within six weeks. Notably, a subgroup that was given a relatively higher dose of the good bug fared even better -- only two of 43 patients (5 percent) suffered another infection. Patients on the therapy had headaches more often than the placebo group, but there was no evidence of serious risks, the research team noted.
After treatment, the good C. difficile bacteria "don't stay around forever," Dr. Gerding said, adding that the therapy may set the stage for patients' normal balance of gut bacteria to flourish again.
Dr. Lawrence Brandt, emeritus chief of gastroenterology at Montefiore Medical Center in New York City, commented on the importance of the findings: "This is a very important study because of the high recurrence rate of C. difficile infections, and because [recurrent] infections become progressively harder to treat."
However, larger studies are needed for the therapy to win approval, according to Dr. Erik Dubberke, a spokesman for the Infectious Diseases Society of America.
The Centers for Disease Control and Prevention (CDC) reported that approximately 500,000 C. diff infections occurred in the United States in 2011, with 83,000 recurrences and 29,000 deaths within 30 days of diagnosis.
Image Credit: Loyola University Chicago Stritch School of Medicine
Published on : Thu, 7 May 2015
Print as PDF
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The iLA Membrane Ventilator is an extrapulmonary ventilation system which is used primarily to remove carbon dioxide. The heart pumps blood through it as it does through a natural organ. The gas exchange takes place via a plasma-tight, heparin-coated...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
Features The SynoVent E3 does not only include advanced ventilator functionality but also a modern, easy to use interface. The display can be configured to suit each clinician’s taste and needs, and gives quick and easy control over ventilator parameters...
FeaturesMindray BeneVision Central Monitoring System is a powerful and scalable solution providing for continuous, real-time surveillance across networks large and small. The system can display patient information from networked monitors, wireless transport...